Welcome to our dedicated page for ENvue Medical news (Ticker: FEED), a resource for investors and traders seeking the latest updates and insights on ENvue Medical stock.
ENvue Medical develops medical technology for enteral care, with a commercial focus on real-time guided bedside feeding tube placement. Its ENvue Navigation Platform is an FDA 510(k)-cleared electromagnetic navigation system for adult use that provides visual guidance as clinicians place feeding tubes into the gastrointestinal tract.
Company news commonly covers hospital adoption, group purchasing and distribution agreements, commercialization updates, and product-line expansion for ENFit syringes and enteral supplies. Updates also include intellectual-property activity tied to feeding tube navigation and the company's surface acoustic wave platform, including acoustic therapeutic technologies such as PainShield and UroShield for pain, bacterial colonization, and biofilm-related applications.
ENvue Medical (NASDAQ: FEED) announced a three-year contract renewal with a leading integrated nonprofit health system operating 12 hospitals in Virginia and North Carolina. The ENvue Navigation Platform has been adopted as the standardized protocol for bedside enteral feeding tube placement across the entire network, embedding the technology into clinical workflow through 2028.
ENvue Medical plans to use this systemwide standardization as a model to pursue similar adoption across additional U.S. health systems.
ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for U.S. Patent Application No. 17/025,969 on May 8, 2026, covering a surface acoustic wave (SAW) ultrasound-enhanced system for transdermal delivery of cannabinoid therapeutics.
The allowed claims span transdermal patch configurations, portable SAW-generating platforms, and methods that the company says produce synergistic enhancement of cannabinoid skin absorption versus patch-only administration. The company says the allowance broadens its IP footprint and could enable future collaborations and applications beyond existing marketed products.
ENvue Medical (NASDAQ: FEED) announced a three-year purchasing agreement renewal with a Group Purchasing Organization covering one of the largest U.S. non-profit health systems operating over 90 hospitals in 17 states. The contract secures contracted access through 2028, simplifying procurement and enabling faster adoption across the network.
The company said the renewal reduces facility-level procurement hurdles and creates a multi-year commercial foundation to drive broader utilization and expand its installed base.
ENvue Medical (NASDAQ: FEED) announced a Virginia 255-bed nonprofit medical center affiliated with the Mayo Clinic Care Network adopted the ENvue™ Navigation Platform, marking ENvue's 40th U.S. hospital customer.
The hospital shifted feeding tube placement from interventional radiology to a nursing-led bedside model using ENvue's FDA 510(k)-cleared electromagnetic navigation for real-time visualization.
ENvue Medical (NASDAQ: FEED) issued a stockholder letter outlining 2025 progress and 2026 priorities. The company reports commercial deployment of its ENvue Navigation Platform across 39 U.S. hospitals, recurring consumable revenue, a February 2026 USPTO Notice of Allowance for a combined electromagnetic-navigation and distal-tip camera feeding tube, and UK reimbursement for UroShield.
Key 2026 priorities include accelerating U.S. commercial adoption, pursuing pediatric and PICC clearances, expanding at-home ENFit syringe distribution, and advancing acoustic therapeutics.
ENvue Medical (NASDAQ: FEED) announced a hospital purchase that expands its U.S. hospital footprint to 39 hospitals by adding a 714-bed teaching hospital and Level I Trauma Center in the Detroit metro area.
The purchase includes the ENvue™ Navigation Platform and feeding tubes; the platform is FDA 510(k) cleared for adult use and provides real-time bedside visualization to assist clinicians during enteral feeding tube placement.
ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for Application No. 18/199,059 titled "Feeding Tube with Electromagnetic Sensor and Camera" on Feb 24, 2026. The allowed patent includes 18 claims combining distal-tip camera imaging, embedded electromagnetic sensing, and MRI safety design elements.
ENvue says the invention aims to enable real-time visualization plus continuous positional tracking to improve placement confidence and support future product development of the ENvue Navigation Platform.
ENvue Medical (NASDAQ: FEED) signed a nationwide distribution agreement with U-Deliver to supply its recently launched over-the-counter reusable ENFit Syringe line through non-acute channels. The syringes are available OTC via U-Deliver website, Amazon storefront, and wholesale in 2.5, 5, 10 and 60 mL sizes.
The ENFit syringes meet ISO 80369-3 standards and are designed for reuse up to seven days or 20 uses, aimed at improving enteral care access in home and long-term care settings.
ENvue Medical (NASDAQ: FEED; NASDAQ: NAOV) announced on January 21, 2026 the appointment of Marc Waldman as Vice President, Commercial to lead U.S. commercialization. Waldman brings 35+ years of medical device commercial leadership, GPO and IDN experience, and sector expertise in patient safety, enteral feeding and neonatal nutrition. He previously grew a neonatal enteral portfolio from $39M to $70M in 3.5 years and will focus on expanding ENvue’s current presence in 38 hospitals and accelerating revenue across the company’s enteral platform.
ENvue Medical (NASDAQ: FEED) announced on January 14, 2026 the launch of over-the-counter ENFit syringes for enteral feeding and medication delivery, available without a prescription. The syringes will be sold in institutional and consumer-friendly packaging and are anticipated to appear at certain online retailers including Amazon and durable medical equipment suppliers. Offered in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, the devices comply with ISO 80369-3 and are designed for reuse for up to seven days or 20 uses, aiming to support continuity of care across clinical and home settings.